Phase 3 Endometrial Cancer Trial, Recruiting NCT06509724 Sponsor: Samsung Medical Center Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 3 Endometrial Cancer Trial, Recruiting

NCT06509724
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with cervical cancer confirmed by a tissue biopsy (histological diagnosis)
  • People whose cervical cancer is one of these specific types: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
  • People who have already had surgery to remove the uterus and nearby lymph nodes (radical hysterectomy and pelvic lymphadenectomy)
  • People whose post-surgery pathology results show at least one of the following: cancer spread to pelvic lymph nodes, cancer involvement in the tissue beside the cervix (parametrium), or cancer cells found at the edges of the removed tissue (positive surgical margins) — meaning radiation therapy after surgery is recommended
  • People aged 20 to 75 years old
  • People who are in good general physical condition, rated 0 or 1 on a standard activity scale (ECOG scale), assessed within one week before joining the study (confirm with trial site)
  • People whose blood counts meet minimum levels: white blood cell component (granulocytes) at or above 1.0 x 10³/µL, platelets at or above 30 x 10³/µL, and haemoglobin at or above 9.5 g/dL
  • People whose kidney and liver function blood test results fall within acceptable ranges: creatinine below 2.0 mg/dL and bilirubin below 1.5 mg/dL
  • People who have voluntarily signed the study consent form

Who may not be able to join:

  • People whose cancer has spread to distant parts of the body, including the ovaries or lymph nodes near the main abdominal artery (para-aortic lymph nodes)
  • People who have previously received radiation therapy to the pelvic area
  • People whose surgery (radical hysterectomy) was performed more than 3 months before joining the study
  • People who have a serious, untreated acute illness — such as stroke, cerebral infarction, or heart attack — unrelated to their cervical cancer
  • People who received chemotherapy before their surgery (neoadjuvant chemotherapy)
  • People who will not be receiving chemotherapy at the same time as their radiation therapy
  • People who have been diagnosed with another cancer in the past 5 years, except for thyroid cancer, skin cancer, or carcinoma in situ (a very early-stage localised cancer)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +82-10-9933-2616

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
19 July 2024
Est. completion
1 July 2027

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Local control rate for the radiation treatment area

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov